Improving Outcomes in Non-Small Cell Lung Cancer

Amivantamab, Chemotherapy Improves PFS in EGFR NSCLC with Exon 20 Mutations

Amivantamab, Chemotherapy Improves PFS in EGFR NSCLC with Exon 20 Mutations

The addition of amivantamab to chemotherapy improved outcomes compared to chemotherapy alone as a first-line treatment for patients with EGFR Exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC)...
Datopotamab Deruxtecan Safe, Effective for Patients with Heavily Pretreated NSCLC

Datopotamab Deruxtecan Safe, Effective for Patients with Heavily Pretreated NSCLC

The antibody-drug conjugate datopotamab deruxtecan demonstrated encouraging antitumor activity in patients with heavily pretreated non-small cell lung cancer (NSCLC)...
Responding Patients with NSCLC Can Safely Discontinue Immunotherapy After 2 Years

Responding Patients with NSCLC Can Safely Discontinue Immunotherapy After 2 Years

Overall survival (OS) outcomes did not significantly differ between patients with advanced non-small cell lung cancer (NSCLC) who received immunotherapy indefinitely or for a fixed duration...

Prior Treatments, Genomic Factors Associated with Sotorasib Response, Toxicity in Real-World Setting

Prior Treatments, Genomic Factors Associated with Sotorasib Response, Toxicity in Real-World Setting

A retrospective study published in JCO Precision Oncology identified factors associated with clinical response and toxicity in patients taking sotorasib for advanced KRASG12C-mutant non-small cell lung cancer (NSCLC)...

Future of Resectable NSCLC Lies in Optimal Treatment Duration, Reliable Surrogate Endpoints

Future of Resectable NSCLC Lies in Optimal Treatment Duration, Reliable Surrogate Endpoints

The future of adjuvant and neoadjuvant treatments for early-stage resectable non-small cell lung cancer will involve identifying biomarkers to determine which patients can benefit from perioperative immunotherapy and targeted therapy...


Loading...

© 2024 /alert® unless otherwise noted. All rights reserved.
Reproduction in whole or in part without permission is prohibited.
Privacy Policy | Terms of Use | Editorial Policy | Advertising Policy